Gene · 2549
Papers2,374
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
301 to 320 of 2,374
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Probabilistic edge inference of gene networks with markov random field-based bayesian learning. | Front Genet | 2022 | 36437931 | PubTator, text mining | PubMed |
| Molecular subgrouping of medulloblastoma in pediatric population using the NanoString assay and comparison with immunohistochemistry methods. | BMC Cancer | 2022 | 36437460 | PubTator, text mining | PubMed |
| A single-cell analysis reveals tumor heterogeneity and immune environment of acral melanoma. | Nat Commun | 2022 | 36433984 | PubTator, text mining | PubMed |
| Role of Long Noncoding RNAs in the Regulation of Cellular Immune Response and Inflammatory Diseases. | Cells | 2022 | 36429069 | PubTator, text mining | PubMed |
| Tumorigenesis Mechanisms Found in Hereditary Renal Cell Carcinoma: A Review. | Genes (Basel) | 2022 | 36421797 | PubTator, text mining | PubMed |
| Regulation of EGF-stimulated activation of the PI-3K/AKT pathway by exocyst-mediated exocytosis. | Proc Natl Acad Sci U S A | 2022 | 36417441 | PubTator, text mining | PubMed |
| The 8p11 myeloproliferative syndrome: Genotypic and phenotypic classification and targeted therapy. | Front Oncol | 2022 | 36408177 | PubTator, text mining | PubMed |
| Modeling (not so) rare developmental disorders associated with mutations in the protein-tyrosine phosphatase SHP2. | Front Cell Dev Biol | 2022 | 36407105 | PubTator, text mining | PubMed |
| Comprehensive Analysis Reveals PTK6 as a Prognostic Biomarker Involved in the Immunosuppressive Microenvironment in Breast Cancer. | J Immunol Res | 2022 | 36405012 | PubTator, text mining | PubMed |
| B cell linker protein (BLNK) is a regulator of Met receptor signaling and trafficking in non-small cell lung cancer. | iScience | 2022 | 36388990 | PubTator, text mining | PubMed |
| miR-23b-3p, miR-124-3p and miR-218-5p Synergistic or Additive Effects on Cellular Processes That Modulate Cervical Cancer Progression? A Molecular Balance That Needs Attention. | Int J Mol Sci | 2022 | 36362337 | PubTator, text mining | PubMed |
| Type 2 Diabetes Mellitus: Pathogenic Features and Experimental Models in Rodents. | Acta Naturae | 2022 | 36348712 | PubTator, text mining | PubMed |
| Reduced expression of FRG1 facilitates breast cancer progression via GM-CSF/MEK-ERK axis by abating FRG1 mediated transcriptional repression of GM-CSF. | Cell Death Discov | 2022 | 36329016 | PubTator, text mining | PubMed |
| Major pathways involved in macrophage polarization in cancer. | Front Immunol | 2022 | 36325334 | PubTator, text mining | PubMed |
| MicroRNA-383: A tumor suppressor miRNA in human cancer. | Front Cell Dev Biol | 2022 | 36313570 | PubTator, text mining | PubMed |
| Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms. | Front Immunol | 2022 | 36311747 | PubTator, text mining | PubMed |
| CDK12 is hyperactivated and a synthetic-lethal target in BRAF-mutated melanoma. | Nat Commun | 2022 | 36309522 | PubTator, text mining | PubMed |
| Current Insights into miRNA and lncRNA Dysregulation in Diabetes: Signal Transduction, Clinical Trials and Biomarker Discovery. | Pharmaceuticals (Basel) | 2022 | 36297381 | PubTator, text mining | PubMed |
| Emerging Role of ERBB2 in Targeted Therapy for Metastatic Colorectal Cancer: Signaling Pathways to Therapeutic Strategies. | Cancers (Basel) | 2022 | 36291943 | PubTator, text mining | PubMed |
| Improved Long-Term Survival of Patients with Recurrent Medulloblastoma Treated with a "MEMMAT-like" Metronomic Antiangiogenic Approach. | Cancers (Basel) | 2022 | 36291912 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2549/papers?page=16